• Ronald Brazg, M.D., F.A.C.E.
• Leslie Klaff, M.D., Ph.D., F.R.C.P., F.A.C.E.
• Allen Sussman, M.D.

Ronald Leonard Brazg, M.D., F.A.C.E.

Personal

Academic Position

Postgraduate Training

Education

Hospital Positions

Board Certifications

Licensure to Practice

Professional Organization Membership

Bibliography

1. Chait A, Brazg RL, and Krauss RM: Increased oxidative susceptibility of LDL subfractions in subjects with the atherogenic lipoprotein phenotype. Arteriosclerosis and Thrombosis 11(5):1425A, 1991.
2. Brazg RL, Duell PB, Gilmore M, Bierman EL, and Chait A: Effects of dietary antioxidants on LDL oxidation in non-insulin-dependent diabetes. Clin Res 40(1):103A, 1992.
3. Zambon S, Brazg RL, Aviram M, Oram JF, and Bierman EL: The effect of probucol on HDL-mediated sterol translocation and efflux from cells. Atherosclerosis 94(1):51-60, 1992.
4. James J. Maciejko, M.S., Ph.D., Ronald Brazg, M.D., Aajay Shah, M.D., et.al.: Psyllium fiber reduces the gastrointestinal symptomatology associated with cholestyramine in the treatment of primary hypercholesterolemia. Arch Fam Med/Vol 1. Sept. 1992.
5. Chait A, Brazg RL, Tribble DL, and Krauss RM: Susceptibility of small, dense low density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am. J. Med - 94 (4) 350-356, 1993.
6. Brazg RL and Bierman EL: Insulin excess counteracts the effects of HDL on intracellular sterol accumulation. Diabetologia, 36:942-947, 1993.
7. Brazg RL: Is Glycemic control enough to control the dyslipidemia in NIDDM. Clinical Diabetes, 11;117, 1993.
8. Brazg RL, Decherney S et al; Safety and efficacy of a novel extended release formulation of metformin in patients with Type II Diabetes – A dose-ranging study. Abstr. Diabetes 49; A99, 2000
9. Insull W Jr, Isaacsohn J, Kwiterovich P, Ra P, Brazg R, Dujovne C, Shan M, Shugrue-Crowley E, Ripa S, Tota R: Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. Cerivastatin Study Group.
J Int Med Res. 2000 Mar-Apr; 28(2):47-68
10. J. Isaacsohn, W. Insull, E. Stein, P. Kwiterovich, P. Ma, R. Brazg, C. Dujovne, M. Shan, E. Shurgrue-Crowley, S. Ripa, R. Tota, for the Cerivastatin Study Group. Clin. Cardiol. Vol 24, (Suppl. IV), IV-1-IV-9, 2001
11. D.B.Hunninghake, M.D.,M.E. McGovern, M.D., M. Koren, M.D., R. Brazg, M.D., D. Murdock, M.D., S. Weiss, M.D., T. Pearson, M.D., Ph.D.: A Dose-Ranging Study of a New, Once-Daily, Dual-Component Drug Product Containing Niacin Extended-Release and Lovastatin. Clinical Cardiology Vol. 26, No. 3, March 2003
12. Feldman B, Brazg R, Schwartz S, Weinstein R: A continuous glucose sensor based on wired enzyme technology-results from a three day trial in patients with Type 1 diabetes. Diabetes Technol. Ther. 2033: 5(5): 769-779
13. Ehlers MR, Klaff LJ, D’Alessio DA, Brazg R, Kay HD, Harley RE, Mathisen AL, Schneider R Recombinant glucagons-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes. Horm Metab Res. 2003 Oct;35 (10):611-6
14. K. Fujioka, R.L. Brazg, I. Raz, S. Bruce, S. Joyal, R. Swanink, M.Pans Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-controlled studies. Diabetes, Obesity and Metabolism, 7, 2005, 28-39
15. Julio Rosenstock, MD, Ronald Brazg, MD, Paula J. Andryuk, BS, Kaifeng Lu, PhD, and Peter Stein, MD, for the Sitagliptin Study 019 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazine therapy in patients with Type 2 diabetes: a 24 week, multicenter, randomized, double-blind, placebo-controlled, parallel group study. Clinical Therapeutics/Volume 28, Number 10, 2006
16. R. Brazg, L. Xu, C. Dalla Man, C. Cobelli, K. Thomas, P.P. Stein Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, To metformin on 24-hour glycaemic control and b-cell function in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 9, 2007, 186-193
17. Weinstein RL, Schwartz SL, Brazg RL, Bugler JR, Peyser TA, McGarraugh GV "Accuracy of the 5-day Freestyle Navigator ® Continuous Glucose Monitoring System: comparison with frequent laboratory reference measurements. Diabetes care. 2007 mar2; [epub ahead of print] pmid: 17337488 [pubmed-as supplied by publisher]
18. Richard L. Weinstein, MD; Sherwyn L. Schwartz, MD; Ronald L. Brazg, MD; Jolyon R. Bugler, MS; Thomas A. Peyser, Ph.D; Geoffrey V. Mcgarraugh, MS The Freestyle Navigator CGMS: Accuracy. The measures made with the freestyle Navigator were consistent and accurate. Review of Endocrinology. June 2008 Cover Story

Educational

1. Cell membrane receptors and their modulation by membrane phospholipids in normal and disease states. Diabetes and Obesity. Diabetes Program, Wayne State University, Detroit, MI, 1986-1987.
2. High density lipoprotein metabolism in human monocytes. Awarded first prize for best scientific presentation, Sinai Hospital, Detroit, MI, 1989-1990.
3. Honored for Contribution to Medical Education, Sinai Hospital, Detroit, MI, 1989
4. Excellence in Teaching Award, Valley Medical Center, 1995
5. Excellence in Teaching Award, Valley Medical Center, 1996
6. “Best Doctors in America” 2002/2003
7. “Best Doctors in America” 2003/2004

Clinical Research